摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-Dimethyl-N-(2-(1-piperazinyl)ethyl)propanamide

中文名称
——
中文别名
——
英文名称
2,2-Dimethyl-N-(2-(1-piperazinyl)ethyl)propanamide
英文别名
2,2-dimethyl-N-(2-piperazin-1-ylethyl)propanamide
2,2-Dimethyl-N-(2-(1-piperazinyl)ethyl)propanamide化学式
CAS
——
化学式
C11H23N3O
mdl
——
分子量
213.32
InChiKey
DRURWHLSUJFBCA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    44.4
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
    申请人:Nishino Taito
    公开号:US20120128640A1
    公开(公告)日:2012-05-24
    An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.
    提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物(其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义)、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂,能够扩张血液干细胞和/或造血祖细胞。
  • NOVEL REGULATORY PROTEINS AND INHIBITORS
    申请人:Greengard Paul
    公开号:US20130149309A1
    公开(公告)日:2013-06-13
    The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates γ-secretase to produce β-amyloid protein (Aβ). Deposition of Aβ has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of Aβ.
    本发明提供了一种以前未被描述的蛋白质(γ-分泌酶激活蛋白或gSAP),该蛋白质能激活γ-分泌酶产生β-淀粉样蛋白(Aβ)。Aβ的沉积与阿尔茨海默病和其他病理有关。因此,本发明还提供了筛选方法和新型研究工具,该蛋白质的抑制剂以及与Aβ沉积相关的阿尔茨海默病和其他神经退行性疾病的诊断、治疗和控制方法。
  • Bis-benzimidazole compounds and methods of using the same
    申请人:THE SCRIPPS RESEARCH INSTITUTE
    公开号:US10961202B2
    公开(公告)日:2021-03-30
    Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.
    本文提供了用于调节基因序列异常重复扩增的化合物和方法。更具体地说,本文提供了 RNA 的抑制剂以及此类抑制剂在调节核苷酸重复扩增中的用途,例如,用于治疗肌营养不良症 1 型 (DM1)、肌营养不良症 2 型 (DM2)、福氏营养不良症、亨廷顿氏病、肌萎缩侧索硬化症或额叶痴呆症。
  • Pyrrole derivatives as PLK1 inhibitors
    申请人:SENTINEL ONCOLOGY LIMITED
    公开号:US11208405B2
    公开(公告)日:2021-12-28
    The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and R7 is selected from R4. The compounds are useful in the treatment of cancers.
    本发明提供了式 (3) 的化合物: 或其药学上可接受的盐或同系物,其中 Z 是一个 5 元杂芳基环,含有一个或两个氮环成员,可选地还含有一个选自 N 和 O 的杂原子环成员; 环 X 是苯环或吡啶环; 环 Y 是苯、吡啶噻吩呋喃环; Ar1 是任选取代的苯、吡啶噻吩呋喃环; m 为 0、1 或 2; n 为 0、1 或 2; R1 选自各种取代基: R2 选自氢和 C1-4 烃基; R3 选自氢和 C1-4 烃基; R4 选自各种取代基; R5 选自各种取代基; Ar2 是任选取代的苯基、吡啶基或吡啶酮基团; R6 是 Q1-Ra-Rb 基团; Q1 不存在或为 C1-3 饱和烃连接体; Ra 选自 O、C(O)、C(O)O、CONRc、N(Rc)CO、N(Rc)CONRc、NRc 和 SO2NRc; Rb 选自氢和各种取代基; R7 选自 R4。 这些化合物可用于治疗癌症。
  • METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS
    申请人:The UNIVERSITY OF TOKYO
    公开号:US20140227780A1
    公开(公告)日:2014-08-14
    An agent for inducing production of megakaryocytes and/or platelets from pluripotent stem cells which is useful for treatment of disease accompanied by a decrease in platelets is provided. A method for producing megakaryocytes and/or platelets, including separating hematopoietic progenitor cells from the septal cells in sac-like structures produced by pluripotent stem cells, and culturing the hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) where R 1 to R 7 , W, X, Y, Z, Ar 1 and n are as defined in the description to differentiate them into megakaryocytes and/or platelets.
查看更多